[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myeloid-leukemia-in-relapsed-or-refractory\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myeloid-leukemia-in-relapsed-or-refractory":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100585746","a-long-term-follow-up-study-of-patients-with-ard103-car-t-cell-therapies-100585746",false,"NCT06906380","A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies","A Long-term Follow-up Study of Patients Enrolled in ARD103_ARCE-CL-P-001 Phase 1\u002F2 Study and Treated With ARD103 CAR-T Cell Therapies","Inclusion Criteria:\n\n* The participant has R\u002FR AML or MDS and has previously received ARD103 CAR-T cell therapies in the parent study.\n* The participant is able to understand and comply with protocol-required study procedures and has provided a written informed consent document.\n\nExclusion Criteria:\n\n* There are no specific exclusion criteria for this study","ALL",{"count":18,"type":19},49,"ESTIMATED","OBSERVATIONAL","This study will evaluate the long-term safety of ARD103 cellular therapies",[23,24,25],"Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukemia, in Relapsed or Refractory","MDS (Myelodysplastic Syndrome)","NOT_YET_RECRUITING","2025-12-04",{"date":29,"type":30},"2025-12-08","ACTUAL",{"date":32,"type":19},"2026-03-15",{"date":34,"type":19},"2040-10-31",{"name":36,"class":37},"ARCE Therapeutics, Inc.","INDUSTRY",3]